0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Amikacin Therapy for Severe Gram-Negative Sepsis: Emphasis on Infections with Gentamicin-Resistant Organisms

FRANCIS P. TALLY, M.D.; THOMAS J. LOUIE, M.D.; WILLIAM M. WEINSTEIN, M.D.; JOHN G. BARTLETT, M.D.; and SHERWOOD L. GORBACH, M.D.
[+] Article and Author Information

Grant support: from Bristol Laboratories, Division of Bristol-Meyers Co.

Presented in part at the 14th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1974, San Francisco, California.

▸Requests for reprints should be addressed to Francis P. Tally, M.D., Tufts-New England Medical Center, 171 Harrison Avenue, Boston, MA 02111.


Sepulveda, California


Ann Intern Med. 1975;83(4):484-488. doi:10.7326/0003-4819-83-4-484
Text Size: A A A

Amikacin (BB-K8) is a semisynthetic derivative of kanamycin which is active in vitro against many gentamicin-resistant Gram-negative bacilli. Twenty-three patients with 25 serious Gram-negative infections were treated with this new aminoglycoside. Twelve infections involved organisms that were resistant to gentamicin. Twenty patients satisfied the criteria for bacteriological and clinical cure. This included 11 of the 12 infections involving gentamicin-resistant Gram-negative bacilli. In 4 urinary tract infections there was a good clinical response, but routine follow-up urine cultures at 30 days were positive. One patient failed on amikacin therapy. Eighth nerve toxicity was detected in two patients. These results indicate that amikacin is effective in the treatment of serious Gram-negative infections and is particularly useful in those involving resistant organisms. Further studies are indicated to evaluate ototoxic potential.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)